Impact of different patterns of nonadherence on the outcome of highly active antiretroviral therapy in patients with long-term follow-up

HIV Medicine

Volumn 10, Issue 6, 2009, Pages 364-369

  Knobel, Hernando ^a   Urbina, O ^a   Gonzalez A ^a   Sorli M L ^a   Montero, M ^a   Carmona, A ^a   Guelar, A ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Adherence; Compliance; Highly active antiretroviral therapy; HIV

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DRUG DOSE REGIMEN; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; RISK FACTORS; SPAIN; TREATMENT FAILURE; VIRAL LOAD;

EID: 67449146275     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2009.00696.x     Document Type: Article

References (29)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services. January 29, 2008; 1-128. Available at: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf
2. Gazzard B. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy (2008). HIV Med 2008; 9: 563-608.
3. Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133: 21-30.
4. Nieuwkerk PT, Oort FJ. Self-reported adherence to antiretroviral therapy for HIV-1 infection and virologic treatment response: A meta-analysis. J Acquir Immune Defic Syndr 2005; 38: 445-448.
5. Press N, Tyndall MW, Wood E et al. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr 2002; 31 Suppl. 3: S112-S117.
6. Wood E, Hogg RS, Yip B et al. The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 2004; 35: 261-268.
7. Hogg RS, Heath K, Bangsberg D et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16: 1051-1058.
8. Garcia de Olalla P, Knobel H, Carmona A, Guelar A, Lopez-Colomes JL, Cayla JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr 2002; 30: 105-110.
9. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43: 939-941.
10. Maggiolo F, Airoldi M, Kleinloog HD et al. Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials 2007; 8: 282-292.
11. Lee SS, Ma K, Chu EKY, Wong KH. The phenomenon of missing doses in a cohort of HIV patients with good adherence to highly active antiretroviral therapy. Int J STD AIDS 2007; 18: 167-170.
12. Knobel H, Alonso J, Casado JL et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: The GEEMA Study. AIDS 2002; 16: 605-613.
13. Carrieri MP, Leport C, Protopopescu C et al. Factors associated with nonadherence to highly active antiretroviral therapy: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. J Acquir Immune Defic Syndr 2006; 41: 477-485.
14. Etard JF, Lanièce I, Fall MB et al. A 84-month follow up of adherence to HAART in a cohort of adult Senegalese patients. Trop Med Int Health 2007; 12: 1191-1198.
15. Parruti G, Manzoli L, Toro PM et al. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS 2006; 20: 48-56.
16. Ostrop NJ, Hallett KA, Gill MJ. Long-term patient adherence to antiretroviral therapy. Ann Pharmacother 2000; 34: 703-709.
17. Nachega JB, Hislop M, Dowdy DW et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006; 43: 78-84.
18. Deschamps AE, Graeve VD, van Wijngaerden E et al. Prevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using a medication event monitoring system. AIDS Patient Care STDS 2004; 18: 644-657.
19. McNabb JJ, Nicolau DP, Stoner JA et al. Patterns of adherence to antiretroviral medications: The value of electronic monitoring. AIDS 2003; 17: 1763-1767.
20. van Wijngaerden E, De Saar V, De Graeve V et al. Nonadherence to highly active antiretroviral therapy: Clinically relevant patient categorization based on electronic event monitoring. AIDS Res Hum Retroviruses 2002; 18: 327-330.
21. Carrieri P, Cailleton V, Le Moing V et al. The dynamic of adherence to highly active antiretroviral therapy: Results from the French National APROCO Cohort. J Acquir Immune Defic Syndr 2001; 28: 232-239.
22. Howard A A, Arnsten JH, Lo Y et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002; 16: 2175-2182.
23. Liu H, Miller LG, Hays RD et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 2006; 41: 315-322.
24. Glass T R, De Geest S, Weber R et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: The Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006; 41: 385-392.
25. Parienti JJ, Massari V, Descamps D et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38: 1311-1316.
26. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: Methods, validity, and applications. J Clin Epidemiol 1997; 50: 105-116.
27. Choo PW, Rand CS, Inui TS et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 1999; 37: 846-857.
28. Harrigan PR, Hogg RS, Dong WW et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191: 339-347.
29. Gross R, Yip B, Re VL III et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 2006; 194: 1108-1114.